A new study examining the aftereffects of a chlorine gas disaster in a South Carolina town gives larger metropolitan areas important insight into what to expect and how to prepare emergency response systems for an accidental or terrorist release of the potentially deadly gas. The study is now available in the January 2009 issue of
Full Post: New study examines effects of chlorine gas disaster in South Carolina
Allergan, Inc. has announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve LATISSE (bimatoprost solution 0.03%) as a treatment for hypotrichosis (or reduced amount of hair) of the eyelashes.
If approved, LATISSE would be the first and only FDA-approved pharmaceutical to enhance eyelash prominence.
“Today’s Advisory Committee recommendation is an important step in the FDA review process to provide consumers with a safe and effective treatment to improve the length, thickness and darkness of natural eyelashes,” said Scott Whitcup M.D., Allergan’s Executive Vice President of Research and Development. “Recently, unapproved eyelash products containing active drug ingredients have appeared on the market. If approved, LATISSE will offer consumers an FDA-approved product which has been extensively studied in well-controlled clinical trials, is manufactured to pharmaceutical standards, is appropriately labeled for use, and is regulated as a prescription product.”
In addition to its unanimous recommendation for approval of LATISSE, the Committee also voted 5-3 (1 abstained vote) in favor of Phase 4 (post-market studies) to assess use in certain patient populations, including patients of younger age and post-chemotherapy patients with loss of eyelashes.
The Committee’s recommendation, although not binding, will be considered by the FDA as it contemplates approval for LATISSE as a treatment for eyelash growth. If approved by the FDA, Allergan anticipates launching LATISSE in 2009.
http://www.allergan.com/
--------------------------------------------------------------------------------------------
Related Posts:
The U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee today voted unanimously to recommend approval of Bausch & Lomb’s besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis. The company has developed this broad-spectrum, anti-infective drop specifically for ophthalmic use. All new chemical entities such as besifloxacin, a fluoroquinolone, must
Full Post: FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop
Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval
Full Post: FDA advisory committee to dscuss PMA for Genzyme’s Synvisc-One
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of
Full Post: Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout
The Female Health Company has announced that the U.S. Food and Drug Administration’s (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted that the company’s second-generation female condom, the FC2 Female Condom, is approvable with a single condition. The Advisory Committee voted 15-0 that the product is approvable with the condition that the FC2
Full Post: FC2 female condom recommended for approval
Mylan Inc. has announced that its subsidiary, Mylan Pharmaceuticals Inc., received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 10 mg and 20 mg. Fluoxetine Capsules, indicated for the treatment of premenstrual dysphoric disorder (PMDD) are the generic version of Eli Lilly’s
Full Post: Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules --------------------------------------------------------------------------------------------
